SAB Biotherapeutics, Inc.
SABSHealthcare|Biotechnology|US
$3.03
+0.09 (+3.06%)
DCF Value
$0.04
Tangible Book / Share
$2.26
Cash / Share
$1.12
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07187531 SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes | Type 1 Diabetes | P2 | Recruiting | 159 | RCT, Double-blind | High Dose SAB-142, Low Dose SAB-142 |
| NCT04518410 ACTIV-2: A Study for Outpatients With COVID-19 | Coronavirus, Covid19 | P2P3 | Completed | 4,044 | RCT, Double-blind | bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg |
| NCT07670650 PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study | Type 1 Diabetes (T1D) | P3 | Not Yet Recruiting | 108 | RCT, Double-blind | SAB-142, Placebo |
| NCT04850898 Study of SAB-176 in Healthy Adult Participants | Influenza A H1N1 | P2 | Completed | 62 | RCT, Double-blind | SAB-176 |
| NCT04468958 Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants | COVID-19, SARS-CoV2 | P1 | Completed | 28 | RCT, Double-blind | SAB-185 |
| NCT04469179 Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19 | COVID-19, SARS-CoV2 | P1 | Unknown | 21 | RCT, Double-blind | SAB-185 |
| NCT06435936 A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo | PHA1A | P1 | Unknown | 28 | RCT, Double-blind | Single Ascending Dose of SAB-176, Single Ascending Dose of Placebo |
| NCT02788188 Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults | Middle East Respiratory Syndrome Coronavirus | P1 | Completed | 38 | RCT, Double-blind | SAB-301 |
| NCT04471038 Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants | Influenza Type A, Influenza Type B | P1 | Completed | 27 | RCT, Double-blind | SAB-176 |